EUVIMEDEUVIMED entdecken
Crossref

Dual‐Mode Hybrid Discharge Plasma‐Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy

Zewei Wang, Xixi Jing, Danqi Zhang, Zimu Yu, Hao Zhang iD, Dingxin Liu, Jishen Zhang, Yongping Shao, Mingzhe Rong, Maksudbek Yusupov, Francesco Tampieri, Paul K Chu

Advanced Healthcare Materials · 2026-02 · 15 (5)

DOI: 10.1002/adhm.202502779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 07.09.2025. Verfasst von Zewei Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, 710049, China. Hauptthemen laut MEDLINE: Immunotherapy, Plasma Gases, Alginates, Melanoma, Experimental. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Taihu Lake Innovation Fund for the School of Future Technology of Xi'an Jiaotong University, City University of Hong Kong Donation Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although cold atmospheric plasma is a promising therapeutic technique for tumor immunotherapy via reactive oxygen and nitrogen species (RONS), the challenges associated with the generation and delivery of these RONS hamper clinical adoption. Herein, a dual‐mode hybrid discharge plasma‐activated sodium alginate hydrosols (PAH SA ) is proposed to enhance the antitumor immune response. Gaseous highly reactive RONS are generated by dual‐mode hybrid plasma produced by mixed O 3 and NO x modes, which are converted into aqueous RONS in PAH SA via gas‐liquid reactions between plasma and hydrosols. In vitro results indicate that compared with O 3 ‐PAH SA and NO x ‐PAH SA , Hybrid‐PAH SA produces greater immunogenic cell death in cancer cells via the release of RONS. It also mediates the polarization of M2‐like macrophages to M1‐like macrophages to improve antitumor effects. In vivo studies confirm that Hybrid‐PAH SA inhibits B16F10 melanoma growth and produces stronger T‐cell‐mediated antitumor immune responses. Thus, Hybrid‐PAH SA offers a promising strategy for enhanced plasma‐induced cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPlasma GasesAlginatesMelanoma, ExperimentalAnimalsMiceMice, Inbred C57BLCell Line, TumorReactive Oxygen SpeciesReactive Nitrogen SpeciesMacrophagesHumansRAW 264.7 Cells

Stichwörter der Autor:innen

cold atmospheric plasmaplasma‐activated hydrosolreactive oxygen and nitrogen speciestumor immunotherapy

Substanzen

Plasma GasesAlginatesReactive Oxygen SpeciesReactive Nitrogen Species

Autor:innen und Institutionen

  • Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, 710049, China.
  • State Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, Xi'an Jiaotong University, Xi'an, Shaanxi, 710049, China.
  • Interdisciplinary Research Center of Frontier Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, 710049, China.
  • Institute of Fundamental and Applied Research, National Research University TIIAME, Kori Niyoziy 39, Tashkent, 100000, Uzbekistan.
  • School of Engineering, Central Asian University, Milliy Bog Street 264, Tashkent, 111221, Uzbekistan.
  • Biomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering and Institute for Research and Innovation in Health (IRIS) and Barcelona Research Centre in Multiscale Science and…

ORCID-Profile: Hao Zhang

Förderung

  • National Natural Science Foundation of China
  • Taihu Lake Innovation Fund for the School of Future Technology of Xi'an Jiaotong University
  • City University of Hong Kong Donation Research
  • Guangdong - Hong Kong Technology Cooperation Funding Scheme
  • Fundamental Research Funds for Central Universities

Zitieren

APA

Wang, Z., Jing, X., Zhang, D., Yu, Z., Zhang, H., Liu, D., Zhang, J., Shao, Y., Rong, M., Yusupov, M., Tampieri, F., & Chu, P. K. (2026). Dual‐Mode Hybrid Discharge Plasma‐Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy. Advanced Healthcare Materials, 15(5). https://doi.org/10.1002/adhm.202502779

Vancouver

Wang Z, Jing X, Zhang D, Yu Z, Zhang H, Liu D, et al. Dual‐Mode Hybrid Discharge Plasma‐Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy. Advanced Healthcare Materials. 2026;15(5). doi:10.1002/adhm.202502779

BibTeX
@article{Wang2026,
  author = {Wang, Zewei and Jing, Xixi and Zhang, Danqi and Yu, Zimu and Zhang, Hao and Liu, Dingxin and Zhang, Jishen and Shao, Yongping and Rong, Mingzhe and Yusupov, Maksudbek and Tampieri, Francesco and Chu, Paul K},
  title = {Dual‐Mode Hybrid Discharge Plasma‐Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/adhm.202502779}
}
Kostenlos starten →